EGFR and non-small cell lung carcinoma: In the NSCLC scenario, about 10–15% of Caucasian cases present somatic sensitizing mutations in the epidermal growth factor receptor (EGFR), for which three generations of tyrosine kinase inhibitors (TKIs) have been developed able to significantly improve patients’ survival outcomes [2].